European commission (ec) extends the approval of evkeeza® (evinacumab) to children as young as 6-months old with homozygous familial hypercholesterolemia (hofh)

First and only medicine approved in the eu for paediatric patients aged 6-months to 5 years old with hofh, an ultrarare, inherited form of high cholesterol first and only medicine approved in the eu for paediatric patients aged 6-months to 5 years old with hofh, an ultrarare, inherited form of high cholesterol
EC Ratings Summary
EC Quant Ranking